The structure of a key enzyme for infectious diseases solved at ESRFAugust 12, 2003A European team of scientists from the University of Dundee (UK), the Technical University of Munich (Germany) and the European Synchrotron Radiation Facility, ESRF, (France) have determined the structure of a key target enzyme for novel drug development to treat infectious diseases including malaria, tuberculosis and sexually transmitted bacterial infections. The results of their collaboration are published on the August 5 issue of Proceedings of the National Academy of Sciences. Synchrotron radiation at the ESRF played a key role in the determination of the structure of the enzyme CDP-ME kinase. The experiment took place on one of the macromolecular crystallography beamlines at the ESRF. This kinase helps to produce many of the molecules that bacteria and parasites need to live and multiply. A molecule that can prevent the kinase from working normally will poison and kill the pathogenic organisms. The determination of the structure of the enzyme provides a template for the design of small molecules that will inhibit its action and prevent it from working normally. In the future, the structure may help lead to the development of new potent therapies for a wide range of microbial infections. "These drugs could potentially help the treatment of not only malaria and tuberculosis but also toxoplasmosis, chlamydia, meningitis and cholera for example", explains Professor Bill Hunter, one of the authors of the article. About the technique Protein crystallography consists of the production of highly pure protein samples. These samples are then crystallised to produce single crystals of the protein. When X-rays interact with single crystals, the interaction between the constituents of the crystal and the X-rays results in the production of an interference pattern - known as a diffraction pattern. By the use of suitable physical and chemical techniques it is possible to use the diffraction patterns in order to determine the spatial distribution of the electrons within the crystal sample. The chemical interpretation of this produces the structural model that reveals the three-dimensional structure of the protein. The ESRF presents substantial improvements for the exploitation of this technique; in particular the use of intense, highly collimated X-ray beams greatly aids the investigation of small weakly diffracting crystals. European Synchrotron Radiation Facility (ESRF) |
|||||||||||||||||||||
| Related Malaria Current Events and Malaria News Articles PATH Malaria Vaccine Initiative shares strategy for developing 'next-generation' malaria vaccines Marking its tenth anniversary year, the PATH Malaria Vaccine Initiative (MVI) today unveiled a new strategy that sets the stage for an aggressive push targeting the long-term goal of eliminating and eradicating malaria. Malaria is one of the world's deadliest infectious diseases, killing nearly 900,000 people a year, most of them children in sub-Saharan Africa. Global challenges and opportunities in fighting HIV/AIDS and neglected diseases Responding to the HIV/AIDS pandemic and tackling so-called neglected tropical diseases are the focus of the November/December 2009 edition of Health Affairs. Media availability: The role of biomedical research in malaria eradication Although malaria has been controlled in many local and regional populations, the permanent elimination of malaria parasites throughout the world remains an elusive goal, and the disease continues to claim nearly one million lives each year. Ineffective monotherapies common in high-burden malarious countries ACTwatch, a research project led by PSI, in collaboration with the London School of Hygiene and Tropical Medicine, released evidence today that indicates that artemisinin combination therapy, the most effective medicines for treating malaria, continue to have a significantly low presence on the market among populations considered to be most at risk. New tool promises more accurate antimalarial drug dosing Scientists at LSTM have developed a tool to support the development of appropriate age-based dosing regimens for malaria drugs. Cell phones become handheld tools for global development Mobile phones are on the verge of becoming powerful tools to collect data on many issues, ranging from global health to the environment. Exon-skipping drug prevents muscle wasting, maintains muscle function in dystrophin deficient mice An exon skipping PPMO has demonstrated dramatic effects in the prevention and treatment of severely affected, dystrophin and utrophin-deficient mice, preventing severe deterioration of the treated animals and extending their lifespan. UM School of Medicine researchers find extreme genetic variability in malaria parasite Researchers at the University of Maryland School of Medicine Center for Vaccine Development (CVD) have charted the extreme genetic differences that occur over time in the most dangerous malaria parasite in the world. Outfoxing pox: Developing a new class of vaccine candidates In the annals of medicine, Edward Jenner's 1796 vaccination of a young boy against smallpox, using fluid from cowpox blisters, remains a landmark case. In a new study, Kathryn Sykes, a researcher at Arizona State University's Biodesign Institute and her colleagues have taken a fresh look at cowpox. Ironing out the genetic cause of hemoglobin problems A gene with a significant effect on regulating hemoglobin in the body has been identified as part of a genome-wide association study, which looked at the link between genes and hemoglobin level in 16,000 people. More Malaria Current Events and Malaria News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||